de Bondt Daniël, Naslazi Emi, Jansen Erik, Kupets Rachel, McCurdy Bronwen, Stogios Christine, de Kok Inge, Hontelez Jan
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Gynecol Oncol. 2025 Apr;195:134-143. doi: 10.1016/j.ygyno.2025.03.008. Epub 2025 Mar 18.
We compared model predictions with independently published primary data from population-based studies on the impact of HPV vaccination on HPV prevalence, cervical cancer and its precursors.
We searched Cochrane Library, EMBASE, MEDLINE, Web of Science for studies concerning high-income countries published between 2005 to June 2, 2023. Relative risk (RR) for HPV-related outcomes comparing the pre-vaccination and post-vaccination periods were collected from observational and modelling studies. The relationship between vaccination coverage and observed relative reductions was determined using meta-regressions, and we compared model prediction to observations.
We identified a total of 5649 potential articles, of which one systematic review, 14 observational studies and 32 modelling studies met our inclusion criteria. A clear relation was found between the RR of HPV diseases related outcomes in the pre- versus post-vaccination era and the vaccination coverage, with 23 out of 28 data points and 19 out of 20 data points showing significant reductions in HPV prevalence and CIN2+ prevalence respectively. Around 67 % (n/N = 12/18) of model predictions were more optimistic on HPV prevalence reductions compared to the 95 % CI of the meta-regression derived from observational studies. For CIN2+ lesions, 48 % (n/N = 31/64) of model predictions for CIN2+ outcomes fell within the 95 % CI.
Model predictions and observational data agree that HPV vaccination can have a substantial impact on HPV related outcomes on a population level. Despite large heterogeneity in observational data and modelling studies, it is particularly encouraging that model predictions on the impact of HPV vaccination on CIN2+ model lesions align with observational studies.
Ontario Health (formerly known as Cancer Care Ontario).
我们将模型预测结果与基于人群研究中独立发表的原始数据进行了比较,这些研究涉及人乳头瘤病毒(HPV)疫苗接种对HPV流行率、宫颈癌及其癌前病变的影响。
我们在考克兰图书馆、EMBASE、MEDLINE、科学网中检索了2005年至2023年6月2日期间发表的关于高收入国家的研究。从观察性研究和模型研究中收集了比较疫苗接种前和接种后时期HPV相关结局的相对风险(RR)。使用meta回归确定疫苗接种覆盖率与观察到的相对降低之间的关系,并将模型预测结果与观察结果进行比较。
我们共识别出5649篇潜在文章,其中1篇系统评价、14项观察性研究和32项模型研究符合我们的纳入标准。在疫苗接种前和接种后时代,HPV疾病相关结局的RR与疫苗接种覆盖率之间存在明显关系,28个数据点中的23个以及20个数据点中的19个分别显示HPV流行率和CIN2 +流行率显著降低。与基于观察性研究得出的meta回归的95%CI相比,约67%(n/N = 12/18)的模型预测在HPV流行率降低方面更为乐观。对于CIN2 +病变,48%(n/N = 31/64)的CIN2 +结局模型预测落在95%CI范围内。
模型预测和观察数据一致认为,HPV疫苗接种可在人群水平上对HPV相关结局产生重大影响。尽管观察性数据和模型研究存在很大异质性,但特别令人鼓舞的是,关于HPV疫苗接种对CIN2 +模型病变影响的模型预测与观察性研究一致。
安大略省卫生厅(前身为安大略省癌症护理局)。